Early UK agency tests on banned silicone filler “encouraging”
This article was originally published in SRA
Executive Summary
The UK Medicines and Healthcare products Regulatory Agency has reported that the preliminary tests it has conducted on the silicone filler used in banned breast implants made by Poly Implant Prothèse (PIP) have revealed “no evidence of genotoxicity or chemical toxicity”1,2.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.